title: Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.
abstract: Treatment as prevention is expected to have a major role in reducing HIV incidence, but other prevention interventions will also be required to bring the epidemic under control, particularly among key populations. One or more forms of pre-exposure prophylaxis (PrEP) will likely play a critical role. Oral PrEP with emtricitabine-tenofovir (Truvada®) is currently available in the US and some other countries, but uptake has been slow. We review the concerns that have contributed to this slow uptake and discuss current and future research in this critical area of HIV prevention research.
authors.affiliation: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC 9831, Bethesda, MD, 20892, USA, burnsda@niaid.nih.gov.
authors.forename: David N
authors.initials: DN
authors.lastname: Burns
authors.forename: Cynthia
authors.initials: C
authors.lastname: Grossman
authors.forename: Jim
authors.initials: J
authors.lastname: Turpin
authors.forename: Vanessa
authors.initials: V
authors.lastname: Elharrar
authors.forename: Fulvia
authors.initials: F
authors.lastname: Veronese
mesh_terms: D000284:Administration, Oral; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D065129:Pre-Exposure Prophylaxis / Q000191:economics / Q000639:trends*
chemical_list: D044966:Anti-Retroviral Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009943:Organophosphorus Compounds; D003841:Deoxycytidine